A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Completed · Phase 3 · Has a placebo group

Conditions studied: Macular Degeneration

In brief

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Key facts

Study ID
NCT02462928
Run by
Allergan
People needed
939
Starts
2015-06-25
Expected to finish
2019-06-19
Last updated by the study team
2020-07-28

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.